1-6 of 6
Olanrewaju O. Okusanya
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

Ashley C. Woods, Kelly J. Norsworthy, Moran Choe, Brenda J. Gehrke, Haiyan Chen, Jonathon Vallejo, Lili Pan, Xiling Jiang, Hongshan Li, Jeffrey Kraft, Jiang Liu, Rosane Charlab, Olanrewaju O. Okusanya, Brian Booth, Richard Pazdur, Marc R. Theoret, R. Angelo de Claro
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 12–17.
https://doi.org/10.1158/1078-0432.CCR-24-2196
Published: 06 January 2025
View article titled, FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an <em>Isocitrate Dehydrogenase 1</em> Mutation
Open the PDF for FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an <em>Isocitrate Dehydrogenase 1</em> Mutation in another window
Includes: Supplementary data
Journal Articles

Project Confirm: Accelerated Drug Approvals for CML—Response

Kendra L. Sweet, Jorge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler, Cristina Ruiz, Charles A. Schiffer, Lori A. Ehrlich, Gulsum E. Pamuk, Joseph Wynne, Gautam U. Mehta, Olanrewaju O. Okusanya, R. Angelo de Claro, Marc R. Theoret, B. Douglas Smith, Kelly J. Norsworthy
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 237–238.
https://doi.org/10.1158/1078-0432.CCR-23-3234
Published: 05 January 2024
View article titled, Project Confirm: Accelerated Drug Approvals for CML—Response
Open the PDF for Project Confirm: Accelerated Drug Approvals for CML—Response in another window
Journal Articles

FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

Andrea C. Baines, Rachel Ershler, Bindu Kanapuru, Qing Xu, Guoxiang Shen, Liang Li, Lian Ma, Olanrewaju O. Okusanya, Natalie E. Simpson, Wanda Nguyen, Marc R. Theoret, Richard Pazdur, Nicole J. Gormley
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (21): 4629–4633.
https://doi.org/10.1158/1078-0432.CCR-22-0618
Published: 01 November 2022
View article titled, FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Open the PDF for FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma in another window
Journal Articles

FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes

Nina Kim, Kelly J. Norsworthy, Sriram Subramaniam, Haiyan Chen, Michael L. Manning, Eliford Kitabi, Justin Earp, Lori A. Ehrlich, Olanrewaju O. Okusanya, Jonathon Vallejo, Brenda J. Gehrke, R. Angelo de Claro, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3411–3416.
https://doi.org/10.1158/1078-0432.CCR-21-4498
Published: 15 August 2022
View article titled, FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes
Open the PDF for FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes in another window
Includes: Supplementary data
Journal Articles

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Donna Przepiorka, Robert Q. Le, Alexei Ionan, Ruo-Jing Li, Ying-Hong Wang, Ramadevi Gudi, Soumya Mitra, Jonathon Vallejo, Olanrewaju O. Okusanya, Lian Ma, Yuching Yang, Paresma Patel, Djelila Mezaache, Rakhi Shah, Anamitro Banerjee, Sherita McLamore, Adam N. Maung, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, R. Angelo De Claro
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2488–2492.
https://doi.org/10.1158/1078-0432.CCR-21-4176
Published: 13 June 2022
View article titled, FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy
Open the PDF for FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy in another window
Includes: Supplementary data
Journal Articles

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

E. Dianne Pulte, Kelly J. Norsworthy, Yaping Wang, Qing Xu, Hisham Qosa, Ramadevi Gudi, Donna Przepiorka, Wentao Fu, Olanrewaju O. Okusanya, Kirsten B. Goldberg, R. Angelo De Claro, Ann T. Farrell, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (13): 3515–3521.
https://doi.org/10.1158/1078-0432.CCR-20-4271
Published: 01 July 2021
View article titled, FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a <em>FLT3</em> Mutation
Open the PDF for FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a <em>FLT3</em> Mutation in another window
Includes: Supplementary data